Portal de investigación
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Zozaya, Neboa
- Arrizubieta Basterrechea, Maria Iciar
- Bollo, Elena
- Castellvi, Ivan
- Espin, Jaime
- Ortego, Norberto
- Rodriguez Portal, Jose Antonio
- Rivero, Agustin
- Marcos-Rodríguez JA
- Verde, Luis
Grupos
Abstract
Objectives Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Methods Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. Results The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 +/- 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 +/- 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Conclusions Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.
Datos de la publicación
- ISSN/ISSNe:
- 0266-4623, 1471-6348
- Tipo:
- Article
- Páginas:
- 64-64
- PubMed:
- 35912833
- Factor de Impacto:
- 0,772 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE CAMBRIDGE UNIV PRESS
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- Interstitial lung diseases; Systemic sclerosis; Pulmonary fibrosis; Multi-criteria decision analysis
Cita
Zozaya N,Arrizubieta MI,Bollo E,Castellvi I,Espin J,Ortego N,POVEDA JL,Rodriguez JA,Rivero A,Marcos JA,Verde L. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. Int. J. Technol. Assess. Health Care. 2022. 38. (1):p. 64-64. IF:3,200. (2).